Mechanistically, we found that CRABP2 can bind to PLAAT4, and the knockdown of CRABP2 causes upregulation of PLAAT4 expression, leading to an overall decrease in lipid metabolic activity, ultimately inhibiting NSCLC cell growth and metastasis. Here, CRABP2 is linked to non-small cell lung carcinoma.